Therapeutic options for COVID-19: a quick review

References

• Organization WH. Coronavirus disease 2019 (COVID-19): situation report, 88. 2020.
   Google Scholar
• Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.
   PubMed Web of Science ®Google Scholar
• Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res. 2020;7(1):1–10.
   PubMed Web of Science ®Google Scholar
• Lu Q, Shi Y. Coronavirus disease (COVID-19) and neonate: what neonatologist need to know. J Med Virol. 2020;92(6):564–7.
   PubMed Web of Science ®Google Scholar
• Pourhossein B, Dabbagh A, Fazeli M. Insights into the SARS-CoV2 outbreak; the great global challenge: a mini review. JCMA. 2020;5(1):23–6.
   Google Scholar
• Terada Y, Matsui N, Noguchi K, Kuwata R, Shimoda H, Soma T, et al. Emergence of pathogenic coronaviruses in cats by homologous recombination between feline and canine coronaviruses. PLoS One. 2014;9(9):e106534.
   PubMed Web of Science ®Google Scholar
• Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109 (5):102433
   PubMedGoogle Scholar
• Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020; 24(4):91–8.
   PubMedGoogle Scholar
• Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020;87(4):281–286.
   Google Scholar
• Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol. 2020;30(7):1346–51.
   PubMed Web of Science ®Google Scholar
• Durket E, Gillen A, Kottwitz J, Munsterman A. Meta‐analysis of the effects of lidocaine on postoperative reflux in the horse. Vet Surg. 2020;49(1):44–52.
   PubMed Web of Science ®Google Scholar
• Imam MU, Azmi NH, Bhanger MI, Ismail N, Ismail M. Antidiabetic properties of germinated brown rice: a systematic review. Ecam. 2012;2012:1–12.
   Google Scholar
• Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, Hui Z. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv. 2020.
   Google Scholar
• Touret F, Gilles M, Barral K, Nougairède A, van Helden J, Decroly E, et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep. 2020;10(1):1–8.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
   PubMed Web of Science ®Google Scholar
• Molina JM, Delaugerre C, Goff JL, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020:30085–8.
   Web of Science ®Google Scholar
• Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat. Med. 2020; 26: 808–809.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020;34:101663.
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020;323(24):2493–502.
   PubMed Web of Science ®Google Scholar
• Lagier J-C, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. Travel Med Infect Dis. 2020;36:101791.
   PubMed Web of Science ®Google Scholar
• Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036–41.
   PubMed Web of Science ®Google Scholar
• Ramireddy A, Chugh H, Reinier K, Ebinger J, Park E, Thompson M, et al. Experience with hydroxychloroquine and azithromycin in the COVID‐19 pandemic: implications for QT interval monitoring. JAHA. 2020;9(12):e017144.
   Google Scholar
• Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2020;1-11. doi:10.1056/NEJMoa2021436
   Web of Science ®Google Scholar
• Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–3. 16
   PubMed Web of Science ®Google Scholar
• Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020;
   Google Scholar
• Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020;49(2):215–9.
   Google Scholar
• Liu K, Tang M, Liu Q, Han X, Jin H, Zhu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):1–4.
   PubMed Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
   PubMed Web of Science ®Google Scholar
• de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020;117(12):6771–6.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78.
   PubMed Web of Science ®Google Scholar
• Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–36.
   PubMed Web of Science ®Google Scholar
• Yethindra V. Role of GS-5734 (Remdesivir) in inhibiting SARS-CoV and MERS-CoV: the expected role of GS-5734 (Remdesivir) in COVID-19 (2019-nCoV)-VYTR hypothesis. Int J Res Pharm Sci. 2020;11(SPL1):1–6.
   Google Scholar
• Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020; 382(19):1787–99.
   PubMed Web of Science ®Google Scholar
• Zhavoronkov A, Aladinskiy V, Zhebrak A, Zagribelnyy B, Terentiev V, Bezrukov DS, et al. Potential COVID-2019 3C-like protease inhibitors designed using generative deep learning approaches. Insilico Med. 2020;307(E1):1-17.
   Google Scholar
• Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020.
   Google Scholar
• Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, Hong Z, Xia J. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study. J Infect. 2020. 81(1):e1–e5.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, Lu J, Xue Y. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020; 81(1):e21–e23.
   PubMed Web of Science ®Google Scholar
• Zhang J-n, Wang W-j, Peng B, Peng W, Zhang Y-s, Wang Y-l, et al. Potential of arbidol for post-exposure prophylaxis of COVID-19 transmission-preliminary report of a retrospective case-control study. CURR MED Sci. 2020;40(3):480– 6. 2020
   PubMed Web of Science ®Google Scholar
• Zhou Q, Chen V, Shannon CP, Wei X-S, Xiang X, Wang X, et al. Interferon-a2b treatment for COVID-19. Front Immunol. 2020;11:1061.
   Google Scholar
• Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30(4):343–13.
   PubMed Web of Science ®Google Scholar
• Ekins S, Lane TR, Madrid PB. Tilorone: a broad-spectrum antiviral invented in the USA and commercialized in Russia and beyond. Pharm Res. 2020;37(4):1–8.
   Web of Science ®Google Scholar
• Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020;179:104811.
   PubMed Web of Science ®Google Scholar
• Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53(3):368–70.
   PubMedGoogle Scholar
• Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.
   PubMed Web of Science ®Google Scholar
• Choy K-T, Wong AY-L, Kaewpreedee P, Sia SF, Chen D, Hui KPY, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178:104786.
   PubMed Web of Science ®Google Scholar
• Ni L, Zhou L, Zhou M, Zhao J, Wang DW. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan. Front Med. 2020;14(2):210–4.
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970–5.
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117 (17):9490–6.
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–9.
   PubMed Web of Science ®Google Scholar
• Wang C, Li W, Drabek D, Okba NM, van Haperen R, Osterhaus AD, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):1–6.
   PubMed Web of Science ®Google Scholar
• Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55 (5):105938.
   PubMed Web of Science ®Google Scholar
• Al‐Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect. 2017;5(1):e00293.
   PubMedGoogle Scholar
• Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.
   PubMed Web of Science ®Google Scholar
• Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–12.
   PubMed Web of Science ®Google Scholar
• Goodman JL, Borio L. Finding effective treatments for COVID-19: scientific integrity and public confidence in a time of crisis. JAMA. 2020;323(19):1899–900.
   PubMed Web of Science ®Google Scholar
• Zhai MZ, Lye CT, Kesselheim AS. Need for transparency and reliable evidence in emergency use authorizations for coronavirus disease 2019 (COVID-19) therapies. JAMA Intern Med. 2020;180(9):1145–6.
   PubMed Web of Science ®Google Scholar
• Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279–83.
   PubMed Web of Science ®Google Scholar
• Srinivasa A, Tosounidou S, Gordon C. Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue? J Rheumatol. 2017;44(3):398.
   PubMedGoogle Scholar
• Costedoat-Chalumeau N, Hulot J-S, Amoura Z, Leroux G, Lechat P, Funck-Brentano C, et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology (Oxford). 2007;46(5):808–10.
   PubMed Web of Science ®Google Scholar
• Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers Y-M. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41(10):919–31.
   PubMed Web of Science ®Google Scholar
• Abdel‐Hamid H, Oddis CV, Lacomis D. Severe hydroxychloroquine myopathy. Muscle Nerve. 2008;38(3):1206–10.
   PubMed Web of Science ®Google Scholar
• Jorge A, Ung C, Young LH, Melles RB, Choi HK. Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. Nat Rev Rheumatol. 2018;14(12):693–703.
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: what treatments are being investigated? BMJ. 2020;368(368):m1252
   PubMedGoogle Scholar
• Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64(5):e00399–20.
   PubMed Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773–9.
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221–18.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of anticancer medicinal products in man. E M A 2017. EMA/CHMP/205/95 Rev.5
   Google Scholar
• Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy. 2020;40(5):416–37.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.
   PubMed Web of Science ®Google Scholar
• Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–303.
   PubMed Web of Science ®Google Scholar
• Chang Chen M, Jianying Huang M, Zhenshun Cheng M, Yongwen Luo M, Jingyi Zhang M, Xinghuan Wang M. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020.
   Google Scholar
• Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). medRxiv. 2020.
   Google Scholar
• Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, et al. Clinical efficacy of arbidol in patients with 2019 novel coronavirus-infected pneumonia: a retrospective cohort study. SSRN ElectrJour. 2020. doi: 10.2139/ssrn.3542148.
   Google Scholar
• Boriskin Y, Leneva I, Pecheur E-I, Polyak S. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008;15(10):997–1005.
   PubMed Web of Science ®Google Scholar
• Guskova T, Glushkov R. Arbidol–a new antiviral, immunomodulator and interferon-inducer. Moscow: Timotech; 1999.
   Google Scholar
• Blair HA. Fedratinib: first approval. Drugs. 2019;79(15):1719–25.
   PubMed Web of Science ®Google Scholar
• Luo W, Li Y-X, Jiang L-J, Chen Q, Wang T, Ye D-W. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmacol Sci. 2020;41 (8):531–43.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1(5):643–51.
   PubMed Web of Science ®Google Scholar
• Wiegrebe W, Kramer WJ, Shamma M. The emetine alkaloids. J Nat Prod. 1984;47(3):397–408.
   Web of Science ®Google Scholar
• S Akinboye E, Bakare O. Biological activities of emetine. Open Nat Prod J. 2011;4(1):8–15.
   Google Scholar
• Grollman AP. Inhibitors of protein biosynthesis V. Effects of emetine on protein and nucleic acid biosynthesis in HeLa cells. J Biol Chem. 1968;243(15):4089–94.
   PubMed Web of Science ®Google Scholar
• Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT, Sandoval-Espinosa C, et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci USA. 2016;113(50):14408–13.
   PubMed Web of Science ®Google Scholar
• Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, et al. Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis. 2015;1(7):317–26.
   PubMed Web of Science ®Google Scholar
• Bosseboeuf E, Aubry M, Nhan T, De Pina J, Rolain J, Raoult D, et al. Azithromycin inhibits the replication of Zika virus. JAA. 2018;10(1):6–11.
   Google Scholar
• Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifirò G. Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines. Drug Saf. 2020;43(8):691–8.
   PubMed Web of Science ®Google Scholar
• Million M, Lagier J-C, Gautret P, Colson P, Fournier P-E, Amrane S, et al. Full-length title: early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;35:101738.
   PubMed Web of Science ®Google Scholar
• Campoli-Richards DM, Brogden RN, Faulds D. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1990;40(3):449–86.
   PubMed Web of Science ®Google Scholar
• Mahmuda A, Bande F, Kadhim Al-Zihiry KJ, Abdulhaleem N, Majid RA, Hamat RA, et al. Monoclonal antibodies: a review of therapeutic applications and future prospects. Trop J Pharm Res. 2017;16(3):713–22.
   Web of Science ®Google Scholar
• Dibo M, Battocchio EC, Dos Santos Souza LM, da Silva MDV, Banin-Hirata BK, Sapla MMM, et al. Antibody therapy for the control of viral diseases: an update. Curr Pharm Biotechnol. 2019;20(13):1108–21.
   PubMed Web of Science ®Google Scholar
• Haghighi AB, Safari A. Anti-tumor necrotic factor antibody for treatment of neuro-Behçet's disease, a case report. Clin Neurol Neurosurg. 2008;3(110):315–6.
   Google Scholar
• Lee W-J, Lee S-T, Moon J, Sunwoo J-S, Byun J-I, Lim J-A, et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics. 2016;13(4):824–32.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 2011;585(23):3699–709.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–97.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580–4.
   PubMed Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542–52.
   PubMed Web of Science ®Google Scholar
• Bh OBE, Retter A, McClintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. 2020.
   Google Scholar
• Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362.
   PubMed Web of Science ®Google Scholar
• Barrett CD, Moore HB, Yaffe MB, Moore EE. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19: a comment. J Thromb Haemost. 2020;18(8):2060–3.
   PubMed Web of Science ®Google Scholar
• Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18(7):1559–61.
   PubMed Web of Science ®Google Scholar
• Barnes P. Corticosteroid effects on cell signalling. Eur Respir J. 2006;27(2):413–26.
   PubMed Web of Science ®Google Scholar
• Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2006;117(3):522–43.
   PubMed Web of Science ®Google Scholar
• Adcock IM, Ito K. Glucocorticoid pathways in chronic obstructive pulmonary disease therapy. Proc Am Thorac Soc. 2005;2(4):313–9.
   PubMedGoogle Scholar